BioCentury
ARTICLE | Company News

Seikagaku, Ferring deal

September 5, 2016 7:00 AM UTC

Seikagaku granted Ferring exclusive rights outside of Japan to develop and commercialize condoliase ( SI-6603), which is in two U.S. Phase III trials to treat sciatica due to lumbar disc herniation. S...